The Phase III trial successfully saw patients achieving clinical remission and stopping rectal bleeding within 28 days.
Shares of Catalyst Pharmaceuticals CPRX gained 16.7% on Wednesday after the company, along with its licensor, SERB, announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback